The AI-pharma gold rush of 2021–2022 was loud, dazzling, and, like many phenomena in tech, perhaps preceded its maturity. Billions of dollars in bets were placed on the promise that artificial ...
(R to L) EY's Ricardo Vilanova, Lila Bioscience's Molly Gibson, Merck's Iya Khalil, Insitro's Mary Rozenman, and Gallop Oncology's Luba Greenwood at BIO 2025. When Google shook the foundations of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results